VoiceOfChina Archives

Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

By Mourabit Halima 2024.01.05

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Ma Jun, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Ma Jun's perspective:

Prediction of HVPG Score for TACE Treatment Outcome in Liver Cancer Based on CT Deep Learning Model

By Mourabit Halima 2023.12.22

From November 10 to 14, 2023, the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was held in Boston, USA. The CHANCE-CHESS series research results, led by Academician Gaojun Teng, President of the Interventional Physicians Branch of the Chinese Medical Association, Director of the Affiliated Zhongda Hospital of Southeast University, and founder of CHANCE, as well as Professor Xiaolong Qi, Assistant Director of the Affiliated Zhongda Hospital of Southeast University and head of CHESS, were orally presented at the conference.

Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

By Mourabit Halima 2023.12.22

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting was grandly held in Boston, USA. In this event, Dr. Wen Xie's team from Beijing Ditan Hospital, Capital Medical University, presented several notable research findings. One of them is a study on the stability of decompensation in patients with chronic hepatitis B and liver cirrhosis treated with entecavir (ETV) [1], which received the Outstanding Abstract Award at the conference. Hepatology Digest reports on these research findings as follows.

Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

By Mourabit Halima 2023.12.22

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was held in Boston, USA. Professor Jing Zhang and her team from Beijing Youan Hospital, Capital Medical University, have long focused on scientific research in chronic liver diseases. Seven research findings from the team were included in the conference and presented in poster form, covering non-alcoholic fatty liver disease (NAFLD) [1-3], cirrhosis [4-5], and hepatitis C [6-7]. "Hepatology Digest" had the privilege of inviting Professor Jing Zhang for an interview at the conference to introduce the research findings, share insights into clinical research, and discuss topics of interest and future research directions. The interview video and some research content are shared below.

AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

By Mourabit Halima 2023.12.22

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023) was held in Boston, USA. Professor Hong Tang's team from West China Hospital of Sichuan University presented multiple research studies in the fields of hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD) at the conference. The research was included in the conference proceedings and presented in the form of posters. Congratulations to the team! Hepatology Digest reports on these research findings, and the relevant content is summarized below.

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

By Mourabit Halima 2023.12.22

The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.

Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

By Mourabit Halima 2023.12.22

From November 10th to 14th, 2023, the annual grand event in the field of hepatology, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023), took place in Boston, USA. The on-site reporting team of "Hepatology Digest" had the privilege of inviting Dr. Wei Rao's team from the Organ Transplant Center of Qingdao University Affiliated Hospital, to introduce the team's achievements, share their experiences at the conference, and discuss future research directions. The interview content is shared below.

Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting

By Mourabit Halima 2023.12.21

From November 10th to 14th, 2023, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was grandly held in Boston, USA. Dr. Qin Ning's team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented 2 posters of distinction and 6 posters on scientific research in the fields of liver injury, fatty liver, hepatitis B, end-stage liver disease, and complications. "Hepatology Digest" hereby reports on some of the research abstracts, providing you with a glimpse of the team's achievements.

Dr. Xuefeng Luo’s Team: Poor Prognosis for Acute Variceal Bleeding with Liver Cancer, Liver Function Grading and Tumor Staging as Major Risk Factors

By Mourabit Halima 2023.12.21

From November 10th to 14th, 2023, the annual highlight of the liver disease field, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, was grandly held in Boston, USA. Several research achievements from Dr. Xuefeng Luo's team at West China Hospital of Sichuan University were included in the conference [1-3], with one poster earning the distinction of "Poster of Distinction." International Liver Disease hereby reports on the team's latest findings exploring the clinical outcomes and prognostic factors in patients with acute variceal bleeding (AVB) combined with liver cell carcinoma (HCC) and liver cirrhosis, providing valuable insights for readers.

Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China

By Mourabit Halima 2023.12.21

Recently, the Liver Disease Department and Pathology Department at the Fifth Medical Center of the People's Liberation Army General Hospital (formerly the PLA Third O2 Hospital) collaborated to achieve a new breakthrough in the clinical treatment of Chronic Drug-Induced Liver Injury (DILI). The research teams, led by Dr. Zhengsheng Zou, Jingmin Zhao, and Dong Ji, previously pioneered the establishment of a 48-week Steroid Stepwise Reduction (48w-SSR) treatment plan for chronic recurrent DILI, demonstrating its efficacy and safety through rigorous Randomized Controlled Trials (RCTs). The results were published in the prestigious journal Alimentary Pharmacology & Therapeutics (a TOP journal in the 1st area of the Chinese Academy of Sciences).